

EQA round: AIM21/26 - Autoimmunity 2

Deadline: 10.4.2026

Setup: all data

AV = assigned value

N_{tot} = total number of the resultsN_{eva} = number of the results assessed

CVP = consensus of all participants

N_{rel} = relative number of the resultsN_{suc} = number of successful results

>>> ... expected result

S_{rel} = relative success

> ... acceptable result

± ... result not assessed

| Test Sample Group | Frequency of the results | | | | Success | | |
|--|--------------------------|------------------|-------------------------|-----------------------------------|------------------|------------------|-------------------------|
| | AV | N _{tot} | N _{rel} [%] | Result | N _{eva} | N _{suc} | S _{rel} [%] |
| Set 1 | | | | | | | |
| (565) ANCA imunofluorescence - prove | | 63 | | | 63 | 63 | 100 |
| Sample A1 | | 63 | | | 63 | 63 | 100 |
| All results | CVP >>> | 63 | 100 | Positive | | | |
| Sample B1 | | 63 | | | 63 | 63 | 100 |
| All results | CVP >>> | 63 | 100 | Positive | | | |
| (574) ANCA IF (ethanol) - semi-quantity | | 54 | | | 0 | | |
| Sample A1 | | 54 | | | 0 | | |
| All results | ± | 1 | 1,9 | titre 10 | | | |
| | ± | 2 | 3,7 | titre 20 | | | |
| | ± | 8 | 15 | titre 40 | | | |
| | ± | 12 | 22 | titre 80 | | | |
| | ± | 11 | 20 | titre 160 | | | |
| | ± | 9 | 17 | titre 320 | | | |
| | ± | 9 | 17 | titre 640 | | | |
| | ± | 2 | 3,7 | titre 1280 | | | |
| Sample B1 | | 54 | | | 0 | | |
| All results | ± | 1 | 1,9 | titre 10 | | | |
| | ± | 3 | 5,6 | titre 20 | | | |
| | ± | 8 | 15 | titre 40 | | | |
| | ± | 14 | 26 | titre 80 | | | |
| | ± | 11 | 20 | titre 160 | | | |
| | ± | 8 | 15 | titre 320 | | | |
| | ± | 6 | 11 | titre 640 | | | |
| | ± | 2 | 3,7 | titre 1280 | | | |
| | ± | 1 | 1,9 | titre 2560 | | | |
| (578) ANCA IF (formalin) - semi-quantity | | 50 | | | 0 | | |
| Sample A1 | | 50 | | | 0 | | |
| All results | ± | 1 | 2 | titre 10 | | | |
| | ± | 2 | 4 | titre 20 | | | |
| | ± | 1 | 2 | titre 40 | | | |
| | ± | 3 | 6 | titre 80 | | | |
| | ± | 15 | 30 | titre 160 | | | |
| | ± | 13 | 26 | titre 320 | | | |
| | ± | 8 | 16 | titre 640 | | | |
| | ± | 7 | 14 | titre 1280 | | | |
| Sample B1 | | 50 | | | 0 | | |
| All results | ± | 1 | 2 | titre 10 | | | |
| | ± | 4 | 8 | titre 20 | | | |
| | ± | 13 | 26 | titre 40 | | | |
| | ± | 10 | 20 | titre 80 | | | |
| | ± | 11 | 22 | titre 160 | | | |
| | ± | 4 | 8 | titre 320 | | | |
| | ± | 3 | 6 | titre 640 | | | |
| | ± | 3 | 6 | titre 1280 | | | |
| | ± | 1 | 2 | titre 2560 | | | |
| (566) ANCA - type of fluorescence | | 62 | | | 62 | 62 | 100 |
| Sample A1 | | 62 | | | 62 | 62 | 100 |
| All results | CVP >>> | 62 | 100 | Cytoplasmic granular fluorescence | | | |
| Sample B1 | | 62 | | | 62 | 62 | 100 |
| All results | CVP >>> | 62 | 100 | Perinuclear fluorescence | | | |
| (569) anti-myeloperoxidase | | 71 | | | 71 | 71 | 100 |
| Sample A1 | | 71 | | | 71 | 71 | 100 |
| All results | CVP >>> | 71 | 100 | Negative | | | |
| Sample B1 | | 71 | | | 71 | 71 | 100 |
| All results | CVP >>> | 71 | 100 | Positive | | | |
| (570) anti-proteinase III | | 71 | | | 71 | 71 | 100 |
| Sample A1 | | 71 | | | 71 | 71 | 100 |
| All results | CVP >>> | 71 | 100 | Positive | | | |
| Sample B1 | | 71 | | | 71 | 71 | 100 |
| All results | CVP >>> | 71 | 100 | Negative | | | |

EQA round: AIM21/26 - Autoimmunity 2

Deadline: 10.4.2026

Setup: all data

| Test Sample Group | Frequency of the results | | | | Success | | |
|---|--------------------------|------------------|-------------------------|-----------------------------|------------------|------------------|-------------------------|
| | AV | N _{tot} | N _{rel} [%] | Result | N _{eva} | N _{suc} | S _{rel} [%] |
| Set 2 | | | | | | | |
| (562) anti-GBM imunofluorescence - prove | | 17 | | | 17 | 17 | 100 |
| Sample A2 | | 17 | | | 17 | 17 | 100 |
| All results | CVP >>> | 17 | 100 | Positive | | | |
| Sample B2 | | 17 | | | 17 | 17 | 100 |
| All results | CVP >>> | 17 | 100 | Negative | | | |
| (567) anti-GBM imunofluorescence - semi-quantity | | 14 | | | 0 | | |
| Sample A2 | | 14 | | | 0 | | |
| All results | | ± | 1 | 7,1 titre 10 | | | |
| | | ± | 4 | 29 titre 40 | | | |
| | | ± | 2 | 14 titre 80 | | | |
| | | ± | 3 | 21 titre 160 | | | |
| | | ± | 3 | 21 titre 320 | | | |
| | | ± | 1 | 7,1 titre 640 | | | |
| Sample B2 | | 14 | | | 0 | | |
| All results | | ± | 13 | 93 titre 0 (not measurable) | | | |
| | | ± | 1 | 7,1 titre 10 | | | |
| (568) anti-GBM other methods - prove | | 44 | | | 44 | 44 | 100 |
| Sample A2 | | 44 | | | 44 | 44 | 100 |
| All results | CVP >>> | 44 | 100 | Positive | | | |
| Sample B2 | | 44 | | | 44 | 44 | 100 |
| All results | CVP >>> | 44 | 100 | Negative | | | |